Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
5-Alpha Reductase Deficiency Market Forecast: What Value Will The Market Reach By 2030?
In recent years, the 5-alpha reductase deficiency market has experienced significant growth. It is projected to expand from $1.5 billion in 2025 to $1.64 billion in 2026, at a compound annual growth rate (CAGR) of 9.6%. The historical growth was driven by factors such as limited awareness of rare genetic disorders, a primary reliance on clinical evaluation for diagnosis, the gradual adoption of hormone testing, increasing hospital-based treatment, and the slow development of specialized surgical procedures.
The market size for 5-alpha reductase deficiency is set to observe significant expansion over the next few years. It is forecast to attain $2.36 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. This growth in the projected period stems from advancements in gene sequencing technologies, an increase in newborn and carrier screening programs, a heightened focus on personalized hormone therapy, the establishment of more specialty clinics for rare disorders, and expanding research in genetic endocrinology. Notable trends for the forecast period include a rise in the early diagnosis of 5-alpha reductase deficiency, increasing awareness of disorders of sexual development, wider adoption of genetic and hormonal testing, the expansion of specialized endocrinology and urology care, and improved accessibility to hormone replacement therapies.
Get A Free Sample Report With In-Depth Market Insights:
5-Alpha Reductase Deficiency Market Expansion Drivers: What’s Shaping Future Growth?
An increasing volume of research and development endeavors within the field of genomics is notably fueling the expansion of the 5-alpha reductase deficiency market. Genomics involves the comprehensive study of an individual’s complete set of genes (genome), encompassing the interactions among these genes and their interplay with the surrounding environment. The application of genomics facilitates the diagnosis of 5-alpha reductase deficiency through the detection of particular genetic mutations linked to the condition. Consequently, genomic research and development efforts are instrumental in both identifying and addressing the disorder. To illustrate, data from February 2025 released by the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, indicated that U.S. research and development spending climbed from $892 billion in 2022 to $940 billion in 2023, representing a $48 billion increment. Hence, the escalating number of research and development initiatives in genomics is set to propel the 5-alpha reductase deficiency market forward.
5-Alpha Reductase Deficiency Market Breakdown By Product Type And Application
The 5-alpha reductase deficiency market covered in this report is segmented –
1) By Diagnosis: Chromosome Analysis, Gene Sequencing, Hormone Tests, Imaging Tests, Genetic Screening, Other Diagnosis
2) By Treatment: Surgery, Vaginoplasty, Feminizing Genitoplasty, Hormone Replacement Therapy, Other Treatments
3) By End-Users: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Chromosome Analysis: Karyotyping, Fluorescence In Situ Hybridization (FISH)
2) By Gene Sequencing: Targeted Gene Panels, Whole Exome Sequencing
3) By Hormone Tests: Testosterone Levels, Dihydrotestosterone (DHT) Levels
4) By Imaging Tests: Ultrasound, MRI
5) By Genetic Screening: Carrier Testing, Newborn Screening
6) By Other Diagnosis: Clinical Evaluation, Family History Assessment
5-Alpha Reductase Deficiency Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies active in the 5-alpha reductase deficiency market are concentrating on developing technologically advanced products, such as consumer-initiated genetic tests, to enable individuals to obtain personal genetic information directly and privately without needing a healthcare provider’s referral. A consumer-initiated genetic test is a type of genetic examination that individuals order straight from a laboratory or testing firm, typically without a healthcare professional’s involvement, to gain insights into their genetic predispositions, ancestry, or health-related characteristics. For example, in July 2023, Quest Diagnostics, a US-based provider of diagnostic information services, launched Genetic Insights, a consumer-initiated genetic test. This new offering aids individuals in evaluating their potential risk of developing certain hereditary health conditions. It incorporates advanced technology and comprehensive support, including personalized health reports and access to genetic counseling. By analyzing a saliva sample, Genetic Insights assesses 36 genes to identify the risk of nearly two dozen hereditary conditions, such as breast and colon cancer, various heart and blood disorders, as well as carrier status for cystic fibrosis, sickle cell anemia, and Tay-Sachs disease. This test is designed to bridge the gaps left by existing consumer genetic tests and utilizes cutting-edge next-generation sequencing (NGS) technology, which can analyze thousands of DNA variants in disease-related genes and examines more regions of a person’s genome compared to traditional microarray testing.
5-Alpha Reductase Deficiency Market Company Landscape And Competitive Strategy
Major companies operating in the 5-alpha reductase deficiency market are F. Hoffmann-La Roche Ltd, Sanofi SA, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Johnson and Johnson Services Inc, Novo Nordisk A S, Regeneron Pharmaceuticals Inc, Roivant Sciences Ltd, Sanofi Genzyme, Shionogi and Co Ltd, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, UCB S A, Vertex Pharmaceuticals Incorporated, Cadila Healthcare Limited, Endo International plc
View The Full 5-Alpha Reductase Deficiency Market Report:
5-Alpha Reductase Deficiency Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the 5-alpha reductase deficiency market in 2025. The regions covered in the 5-alpha reductase deficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.